Full Press Release Details
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) --BioCardia®, Inc.[NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2025 by conference call on Wednesday, November 12, 2025 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating tohttps://dpregister.com/sreg/10204565/1005a9b26d8.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link:https://event.choruscall.com/mediaframe/webcast.html?webcastid=v3qWCosD.
A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 26, 2025 at the following link:https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 4273038.About BioCardia®BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP®autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visitwww.biocardia.com.